ClinicalTrials.gg
RecruitingNCT07133828Updated May 6, 2026

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

A Phase 1 interventional study of BIIB142 and BIIB142-Matching Placebo in Healthy Volunteer, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

In this study, researchers will learn more about the safety of BIIB142 and how it is processed in the body. This is the first time that researchers will learn about BIIB142 and how it affects people.

The main question researchers want to answer in this study is:

  • How many participants have adverse events (AEs) and serious adverse events (SAEs)?

An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.

Researchers will also learn more about:

  • How the body processes BIIB142

This is a "dose escalation study." This is a study in which increasing amounts of the study drug are given to different groups of participants. This is done until researchers find the highest dose that does not cause harmful effects.

First, participants will be screened to check if they can join the study. The screening period will be up to 28 days. This study will be split into 2 parts - Part A and Part B.

During Part A:

  • Participants will be randomly placed into 1 of 6 groups to receive a single dose of either BIIB142 or a placebo. A placebo looks like the study drug but contains no real medicine.
  • Participants in Groups 1 through 5 will take either BIIB142 or the placebo without food. Participants in Group 6 will take 2 doses of their assigned treatment - once with food and once without food.
  • Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
  • Participants will stay at their study research center for 5 days. They will return for another 4 visits. Each participant in Part A will be in the study for up to 58 days.

During Part B:

  • Participants will be randomly placed into 1 of 3 groups to receive BIIB142 or the placebo. In Part B, participants will take BIIB142 or the placebo once a day for 14 days.
  • Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
  • Participants will stay at their study research center for 16 days. They will return for another 4 visits. Each participant in Part B will be in the study for up to 58 days.
Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of BIIB142 in healthy adult participants.

The secondary objective of this study is to evaluate the pharmacokinetics (PK) profile of single and multiple ascending oral doses of BIIB142 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Have a between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, at screening.
  • Weight ≥ 50 kilograms (kg) at screening.
  • Negative polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in prior to randomization.
  • Must be in good health as determined by the Investigator.

Key Exclusion Criteria:

  • History of any cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • History of severe allergic or anaphylactic reactions
  • History of or ongoing malignant disease (with limited exceptions)
  • Systolic blood pressure >150 millimeters of mercury (mmHg) or \<90 mmHg.
  • Clinically significant (as determined by the Investigator) (ECG) abnormalities.
  • History of or positive test for (HIV).
  • Chronic, recurrent, or serious infection within 90 days prior to Screening.
  • Symptoms of bacterial, fungal, or viral infection within 14 days prior to Screening.
  • Any live or attenuated immunization within 14 days prior to Screening.
  • Use of prescription medications, over-the-counter medications that alter hepatic or renal clearance, or nutraceuticals within 28 days prior to Check-in.
  • MAD Cohorts only: Suicidal ideation with some intent to act within 6 months prior to the start of Screening or history of suicidal behavior within one year prior to Screening.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A

    Participants will receive Dose A of BIIB142 or a matching placebo on Day 1 in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part A (SAD): BIIB142 Cohort 2A

    Participants will receive Dose B of BIIB142 or a matching placebo on Day 1 in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part A (SAD): BIIB142 Cohort 3A

    Participants will receive Dose C of BIIB142 or a matching placebo on Day 1 in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part A (SAD): BIIB142 Cohort 4A

    Participants will receive Dose D of BIIB142 or a matching placebo on Day 1 in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part A (SAD): BIIB142 Cohort 5A

    Participants will receive Dose E of BIIB142 or a matching placebo on Day 1 in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part A (SAD): BIIB142 Cohort 6A

    Participants will receive BIIB142 on Day 1 in the fasted followed by fed state in the first sequence, and vice versa in the second sequence. A washout period of 14 days will be maintained between both the sequences. Dose will be determined based on emerging PK data.

    Drug: BIIB142

  • Experimental
    Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B

    Participants will receive Dose A of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part B (MAD): BIIB142 Cohort 2B

    Participants will receive Dose F of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

  • Experimental
    Part B (MAD): BIIB142 Cohort 3B

    Participants will receive Dose D of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

    Drug: BIIB142 · Drug: BIIB142-Matching Placebo

Interventions

  • DrugBIIB142

    Administered Orally

  • DrugBIIB142-Matching Placebo

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

  2. Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

  3. Number of Participants with Potentially Clinically Relevant Abnormalities in Vital Sign Parameters

    Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

  4. Number of Participants With Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    Time frame: Part B (MAD): Up to Day 29

  5. Number of Participants With Potentially Clinically Relevant Abnormalities in 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

Secondary outcomes

  1. Plasma Concentration of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  2. Area Under the Concentration-Time Curve (AUC) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  3. Maximum Observed Concentration (Cmax) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  4. Time to Maximum Observed Concentration (Tmax) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  5. Apparent Clearance (CL/F) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  6. Apparent Volume of Distribution (Vz/F) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

  7. Elimination Half-Life (t1/2) of BIIB142

    Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

07

Study locations

1 of 1 sites recruiting
  • PPD Development, LP
    Las Vegas, Nevada 89113, United States
    Recruiting
    • · Contact702-963-1600
    • Shawn Searle · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Aug 6, 2026
CompletionEst.
Aug 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07133828
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Aug 29, 2025
Primary completion
Aug 6, 2026 (estimated)
Completion
Aug 6, 2026 (estimated)
Last update
May 6, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion